Asciminib

Chemical formula: C₂₀H₁₈ClF₂N₅O₃ Molecular mass: 449.84 g/mol PubChem compound: 72165228

Therapeutic indications

Asciminib is indicated for:

Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP)

Population group: only adults (18 years old or older)

Asciminib is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

80 mg once daily or 40 mg twice daily at approximately 12-hour intervals

Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase with the T315I mutation

Population group: only adults (18 years old or older)

Chronic myeloid leukemia

For this indication, competent medicine agencies globally authorize below treatments (click for details):

200 mg twice daily at approximately 12-hour intervals

Contraindications

Asciminib is contraindicated in the following cases:

Lactation

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.